When PTSD Treatment Affects Your Physical Health
Most conversations about PTSD medication focus on whether a drug reduces symptoms. Fewer conversations focus on what that drug might be doing to your body in the background. If you have been prescribed a second-generation antipsychotic (SGA) as part of your PTSD treatment, this is worth your attention.
SGAs such as quetiapine, olanzapine, and risperidone are not first-line treatments for PTSD, but they are frequently prescribed as augmentation, meaning they are added on top of an antidepressant to target symptoms like nighttime distress, anger, or dissociation. They can be genuinely helpful for some people. The problem is that they carry a well-documented but under-discussed risk of causing metabolic syndrome.
What Is Metabolic Syndrome?
Metabolic syndrome is not a single disease. It is a cluster of physical changes that, when they occur together, significantly raise your risk of type 2 diabetes, heart disease, and stroke. The five markers are:
- Increased waist circumference (central or abdominal weight gain)
- Elevated blood triglycerides
- Low HDL (good) cholesterol
- High blood pressure
- Elevated fasting blood glucose
Having three or more of these markers meets the clinical threshold for metabolic syndrome. Research examining antipsychotic use and metabolic outcomes consistently shows that SGAs accelerate the development of these markers, sometimes within weeks of starting the medication.
Why Do Antipsychotics Cause This?
The mechanisms are not fully understood, but several pathways are involved. SGAs block histamine H1 receptors, which increases appetite and promotes fat storage. They also interfere with dopamine and serotonin signalling in ways that affect how the body handles insulin. Some SGAs directly impair insulin secretion from the pancreas, independent of weight gain. This means that even people who do not gain significant weight can still develop glucose dysregulation.
Olanzapine and clozapine carry the highest metabolic risk among SGAs. Quetiapine sits in the moderate range. Aripiprazole and ziprasidone tend to have lower metabolic impact, though no SGA is entirely free of this concern. A detailed review of antipsychotic metabolic effects outlines how these risks differ across individual drugs and why monitoring matters.
Why PTSD Patients Face Compounded Risk
People living with PTSD already face elevated rates of cardiovascular disease, obesity, and type 2 diabetes compared to the general population. The chronic stress load associated with PTSD affects cortisol output, inflammatory pathways, and insulin sensitivity independently of any medication. Adding an SGA into that context means the metabolic risks are not simply additive; they may compound each other.
There is also a practical issue: people managing PTSD symptoms often find it harder to maintain the physical activity and dietary patterns that buffer against metabolic changes. This is not a character failing. It is a realistic consequence of living with a condition that affects motivation, energy, and daily functioning. Accounts of people navigating how early trauma shapes long-term physical and psychological health reflect just how intertwined these challenges become over time.
What Monitoring Should Look Like
If you are taking an SGA for PTSD, you should be receiving regular metabolic monitoring. In practice, this does not always happen consistently. Advocate for yourself by asking your prescribing doctor about the following at each review:
- Fasting blood glucose and HbA1c (a longer-term glucose marker)
- Fasting lipid panel (triglycerides, HDL, LDL, total cholesterol)
- Blood pressure and waist circumference
- Body weight and BMI
Baseline measurements should be taken before starting an SGA, then repeated at 12 weeks and every six to twelve months after that. Guidelines on metabolic monitoring for antipsychotic-treated patients recommend this schedule as a minimum standard of care.
Having an Honest Conversation With Your Doctor
Metabolic side effects are a legitimate reason to revisit your medication plan. If your markers are shifting in a concerning direction, your prescriber may consider switching to a lower-risk SGA, adjusting the dose, or exploring whether the augmentation is still necessary given your current symptom picture.
This is not about refusing medication that helps you. It is about making sure the full picture of your health, physical and psychological, is part of the decision. You are entitled to that conversation, and a good prescriber will welcome it.
